From intracellular processing to renal phenotypes: a mechanism-informed framework for interpreting kidney injury and electrolyte patterns with antibody–drug conjugates in solid tumors

Le résumé fourni par la source

Background: Antibody-drug conjugates (ADCs) have transformed solid-tumor therapy and are increasingly benchmarked directly against physician's-choice chemotherapy. However, kidney adverse events and electrolyte disturbances remain inconsistently captured across trials and are often interpreted without a unified pharmacological framework. Objective: This review proposes a mechanism-informed narrative framework linking ADC architecture, intracellular processing, and payload exposure pathways to renal injury and electrolyte phenotype hypotheses while contextualizing these patterns against canonical renal-electrolyte programs of conventional cytotoxic chemotherapy. Approach: We conducted a targeted literature review prioritizing randomized or registrational trials, regulatory labels, real-world or pharmacovigilance data when informative, and phenotype-defining case reports supported by urinary indices, biopsy, or both when available. Evidence is presented using explicit source-level stratification rather than quantitative pooling. Key Messages: Intact ADCs are IgG-based macromolecules with limited glomerular filtration under an intact filtration barrier, whereas released small-molecule payloads or payload-containing catabolites may gain a filtration advantage and create proximal tubular exposure. Comparative studies support toxicity redistribution rather than uniform toxicity reduction. Enfortumab vedotin most often illustrates a systemic/prerenal acute kidney injury (AKI) axis driven by hyperglycemia, diabetic ketoacidosis, infection, and dehydration; sacituzumab govitecan combines gastrointestinal volume depletion with rare biopsy-proven acute tubulointerstitial nephritis; and trastuzumab deruxtecan has generated a hypothesis-defining Fanconi-like proximal tubule signal. Kidney tissue, especially the proximal tubule, contains protease-rich endolysosomal and apical brush-border systems that make renal processing of ADC-derived material biologically plausible, but kidney-specific proof remains limited. Because creatinine-based endpoints may miss mild tubular injury, future ADC programs should consider electrolyte-focused monitoring and the exploration of tubular injury biomarkers. Conclusion: A trafficking-aligned taxonomy may improve the interpretation of ADC-associated renal and electrolyte events. Kidney Disease: Improving Global Outcomes (KDIGO)-aligned kidney endpoints, standardized electrolyte reporting, and prospective validation of tubular injury biomarkers should be priorities for future ADC trials.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.